Date/Time |
05/27 / 22:00 |
Chg. / Chg.(%) |
1.9800 / +0.97% |
Bid |
200.0000 / 200 |
Ask |
210.0000 / 600 |
Open |
205.2600 |
Previous Close |
204.2200 |
High |
207.3624 |
Low |
203.1300 |
Volume [USD] |
131,042,048.8028 |
Volume [Units] |
1,013,333 |
Price fixings |
3378 |
ISIN |
US09062X1037 |
Security |
BIIB |
Exchange |
NASDAQ |
Type |
Stock |
- Biogen revenue slips 6% to $2.53B in Q1
05/03/2022 / 13:09 - TeleTrader
-
- BIIB 10-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Biogen Inc. (BIIB) Investors with Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Class Action
03/29/2022 / 15:36 - GlobeNewswire
-
- Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis
03/28/2022 / 13:30 - GlobeNewswire
-
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against ELMS, TAL, New Oriental, and Biogen and Encourages Investors to Contact the Firm
03/28/2022 / 03:00 - GlobeNewswire
-
- Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer
03/22/2022 / 12:00 - GlobeNewswire